Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Personal Genome Diagnostics, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Personal Genome Diagnostics, Inc.

Regulatory records
1
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 1 FDA record to the applicant name Personal Genome Diagnostics, Inc.. It includes 1 original PMA approval. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jul 30, 2026 to Jul 30, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code PQP appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P250036, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: 3600 Boston St., Suite 10, Blatimore, MD, 21224. Recorded on P250036, decision dated Jul 30, 2026.

Changes described in PMA records

P250036: PGDx elio tissue complete CDx

FDA’s recorded scope: PGDx elio tissue complete CDx is a qualitative next-generation sequencing-based in vitro diagnostic device that uses a high-throughput hybridization-based capture technology utilizing DNA isolated from formalin-fixed paraffin embedded tumor tissue. The PGDx elio tissue complete CDx targeted panel can detect single nucleotide variants, small insertions and deletions, copy number amplifications, and translocations. It is intended to be used as a companion diagnostic to identify melanoma patients who may benefit from treatment with the targeted therapies listed in Table 1.1 below in accordance with the approved therapeutic product labeling.

Jul 30, 2026

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

  1. PGDx elio tissue complete CDx

    P250036 · PMA decision
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.